AIM: Sorafenib is the standard of care in advanced hepatocellular carcinoma. This study was aimed to identify clinical parameters that may predict survival in these patients. MATERIALS & METHODS: In this observational study, a training (226 patients) and validation cohorts (54 patients) were analyzed for evaluating pretreatment and on-treatment parameters. RESULTS: At multivariate analysis, only on-treatment variables (skin toxicity, diarrhea and arterial hypertension - sorafenib off-target effects), alphafetoprotein and radiological responses predicted survival. Using the occurrence of off-target effects, a prognostic index able to distinguish three groups of patients with different survival was constructed and externally validated. CONCLUSION: In hepatocellular carcinoma patients, on-treatment variables are the best predictors of survival. Among these, sorafenib off-target effects may be the most useful indicators for prognostication in field practice.
AIM: Sorafenib is the standard of care in advanced hepatocellular carcinoma. This study was aimed to identify clinical parameters that may predict survival in these patients. MATERIALS & METHODS: In this observational study, a training (226 patients) and validation cohorts (54 patients) were analyzed for evaluating pretreatment and on-treatment parameters. RESULTS: At multivariate analysis, only on-treatment variables (skin toxicity, diarrhea and arterial hypertension - sorafenib off-target effects), alphafetoprotein and radiological responses predicted survival. Using the occurrence of off-target effects, a prognostic index able to distinguish three groups of patients with different survival was constructed and externally validated. CONCLUSION: In hepatocellular carcinomapatients, on-treatment variables are the best predictors of survival. Among these, sorafenib off-target effects may be the most useful indicators for prognostication in field practice.
Authors: Samantha Armstrong; Tina Roy; Bhavana Singh; Monika Kulasekaran; Fatima Shaukat; Xue Geng; Hongkun Wang; Petra Prins; Reena C Jha; Marion L Hartley; Aiwu Ruth He Journal: J Cancer Res Clin Oncol Date: 2022-06-30 Impact factor: 4.553
Authors: Riccardo Giampieri; Michela Del Prete; Tiziana Prochilo; Marco Puzzoni; Valeria Pusceddu; Fabiana Pani; Elena Maccaroni; Roberta Mascia; Maria Giuditta Baleani; Tania Meletani; Rossana Berardi; Anna Maria Lanzillo; Stefano Mariotti; Alberto Zaniboni; Stefano Cascinu; Mario Scartozzi Journal: Sci Rep Date: 2017-04-05 Impact factor: 4.379
Authors: Young Youn Cho; Su Jong Yu; Hye Won Lee; Do Young Kim; Wonseok Kang; Yong-Han Paik; Pil Soo Sung; Si Hyun Bae; Su Cheol Park; Young Seok Doh; Kang Mo Kim; Eun Sun Jang; In Hee Kim; Won Kim; Yoon Jun Kim Journal: J Hepatocell Carcinoma Date: 2021-06-18
Authors: Giorgia Marisi; Alessandro Cucchetti; Paola Ulivi; Matteo Canale; Giuseppe Cabibbo; Leonardo Solaini; Francesco G Foschi; Serena De Matteis; Giorgio Ercolani; Martina Valgiusti; Giovanni L Frassineti; Mario Scartozzi; Andrea Casadei Gardini Journal: World J Gastroenterol Date: 2018-09-28 Impact factor: 5.742